Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.

Future oncology (London, England) - 1 Jan 2021

Li Ji, Dong Wen, Liu Li Na, Huang Yi Jiang, Xiao Mei Fang

Abstract excerpt

Background: We aimed to determine whether circulating tumor cells (CTCs) and cell-free DNA (cfDNA) aids in prognosis of relapse-free survival (RFS). Methods: Non-small cell lung cancer patients with ALK mutations were recruited prospectively. CTCs and cfDNA were quantified at different time points. RFS was estimated and correlated. Results: Baseline median CTCs and cfDNA were 16 cells and 57 ng/mL and declined to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Liquid Biopsy

Share to Neoplasm Recurrence, Local

Share to Neoplastic Cells, Circulating

Share to Pneumonectomy

Share to Postoperative Period

Source

Identifiers

PMID: 32988235
DOI: 10.2217/fon-2020-0554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.PMID 32988235Read ↗

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis.Semantic proximity Read ↗

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.Semantic proximity Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ALK Status Assessment with Liquid Biopsies of Lung Cancer PatientsSemantic proximity Read ↗

Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patientsSemantic proximity Read ↗

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysisSemantic proximity Read ↗

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.Semantic proximity Read ↗

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Semantic proximity Read ↗

CCR7-Positive Circulating Tumor Cells as a Biomarker for Predicting Lung Cancer RiskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.